Phenomics-Driven Discovery that Validates New Targets for
Clinical Success
We partner with pharmaceutical companies to validate new targets, develop novel assets, and optimize them for clinical study using our phenotypic drug discovery platform, Elion.
Elion has already discovered novel targets and advanced precision medicines in cardiovascular, neurological and rare diseases. Learn more about opportunities to partner below.
BENEFITS FOR PHARMACEUTICAL PARTNERS
Develop novel therapeutics from a de-risked pipeline of targets and hits across cardiovascular, neurological, and rare diseases.
Initiate target discovery for new therapeutic programs using one of the only phenotypic drug discovery platforms available with unique clinical data.
Improve clinical study design and strategy to support existing assets leveraging our proven machine learning models for patient stratification and biomarker discovery.
PROGRAMS FOR PARTNERING
Atherosclerosis | Cardiomyopathy | Epilepsy | Heart Failure | Parkinson’s | Kidney Disease
SOME OF OUR PHARMACEUTICAL PARTNERS
Interested in working with us?
Email us at partners@biosymetrics.com with a bit about your organization and goals.